Amplia Therapeutics Ltd has released a press release.
Rights Issue Investor Slide Deck
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
In the deck
Earlier from Amplia Therapeutics
- Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
- Update on ACCENT Trial in Pancreatic Cancer
- FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
- Amplia Reports First Patient Dosing In Phase 2a Accent Trial
- Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
Later from Amplia Therapeutics
- $4.27m Offer Successfully Completed and ACCENT Trial Update
- Preliminary Final Report and Annual Report YE 31 March 2024
- First 26 Patients recruited in Phase 2A ACCENT Trial
- Sustained Reduction in Tumour Size Seen In Pancreatic Trial
- Additional Patient Response in Pancreatic Cancer Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics